Lenalidomide enhances NK cell and monocyte-mediated antibody-dependent cellular cytotoxicity (47), inhibits the proliferation and function of regulatory T cells (48), and increases functional CD8+ and CD4+ T cells in CLL patients (49). Here, CD8A is linked to B-cell chronic lymphocytic leukemia.